GlassScriptPhysician profile
Stephen J Despins
NPI 1366974487
$620.09
in general payments reported to CMS, 2019-2025
13 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.06 · 2023: $120 · 2024: $355 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105.51 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.40 | 2023-2024 | Caplyta |
| Bioventus LLC | $77.03 | 2022-2024 | Durolane, Durolane |
| Lilly USA, LLC | $58.53 | 2024 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $55.00 | 2023-2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $44.59 | 2023-2024 | Ingrezza |
| Dexcom, INC. | $41.75 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $35.17 | 2023-2025 | Rexulti |
| Ascendis Pharma Endocrinology INC | $24.68 | 2025 | Yorvipath |
| Novo Nordisk INC | $23.60 | 2024 | |
| Corcept Therapeutics | $22.53 | 2025 | Korlym |
| Abbott Laboratories | $22.31 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $17.99 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Despins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.